Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-08
2005-02-08
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S194000, C514S355000, C514S356000, C546S273400, C546S315000, C546S321000
Reexamination Certificate
active
06852742
ABSTRACT:
The present invention is directed in part towards methods of modulating the function of calcium channels with pyridine- or 1,4-dihydropyridine-based compounds. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to pyridine- or 1,4-dihydropyridine-based compounds and pharmaceutical compositions comprising these compounds.
REFERENCES:
patent: 0 220 653 (1987-05-01), None
patent: 0 493 782 (1992-07-01), None
Kumar et al, Molecular Pharmacology, vol. 61, No. 3, pp. 649-658, 2002.*
Akaike, N. et al., Low-voltage-activated calcium current in rat aorta smooth muscle cells in primary culture, J. Physiol. 416:141-160 (1989).
Bean, B. P., Nitrendipine block of cardiac calcium channels: high affinity binding to the inactivated state. Proc. Natl. Acad. Sci. USA 81:6388-6392 (1984).
Bech-Hansen, N. T. et al., Loss-of-function mutations in a calcium channel α1-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness, Nat. Genet. 19:264-267 (1984).
Bourinet, E. et al., Splicing of alpha-1a subunit gene generates phenotypic variants of P-and Q-type calcium channels, Nat. Neurosci. 2:407-415 (1999).
Carbone, E. and H. D. Lux, A low voltage-activated, fully inactivating Ca channel in vertebrate sensory neurones, Nature 310:501-502 (1984).
Catterall, W. A., Structure and regulation of voltage-gated Ca2+channels, Annu. Rev. Cell. Dev. Biol. 16:521-555 (2000).
Chaung, R.S.I., et al., Inhibition of T-type voltage gated calcium channel by a new scorpion toxin, Nature Neuroscience, 1:668-674 (1998).
Clozel, J. P., et al., Discovery of main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker, Journal of Hypertension 15:S17-S25 (1997).
Dubel, S. J. et al., Molecular cloning of the alpha-1 subunit of an omega-conotoxin-sensitive calcium channel, Proc. Natl. Acad. Sci. USA. 89:5058-5062 (1992).
Dunlap, K. et al., Exocytototic Ca2+channels in mammalian central neurons, Trends. Neurosci. 18:89-98 (1995).
Fingl et al. in, The Pharmacological Basis of Therapeutics, Ch. 1 p. 1 (1975).
Goldmann, S. and J. Stoltefuss, 1,4-Dihydropyridines: effects of chirality and conformation on the calcium antagonist and calcium agonist activities, Angewandte Chemie International Edition (English) 30:1559-1578 (1991).
Janis, R. A. and Triggle, D. J., Drugs acting on calcium channels, in Calcium Channels: Their Properties, Functions, Regulation and Clinical Relevance, ch. 13, pp. 195-249 (1990).
Janis, R.A., and D. J. Triggle, New developments in Ca2+channel antagonists, Journal of Medicinal Chemistry, 26:775-785 (1983).
Klugbauer, N. et al., Molecular diversity of the calcium channel alpha 2 delta subunit, J. Neurosci. 19:684-691 (1999).
Klugbauer, N. et al., A family of gama-like calcium channel subunits, FEBS Lett. 470:189-197 (2000).
Kumar, P.P. et al., Synthesis and Evaluation of a New Class of Nifedipine Analogs with T-Type Calcium Channel Blocking Activity, Molecular Pharmacology 61-6:649-657 (2002).
Lacinova, L. et al., Regulation of the calcium channel alpha 1G subunit by divalent cations and organic blockers, Neuropharmacology 39:1254-1266 (2000).
Lacinova, L. et al., Low voltage activated calcium channels: from genes to function, Gen. Physiol. Biophys. 19:121-136, Review (2000).
Loev, B., et al., “Hantzsch-type” dihydropyridine hypotensive agents, Journal of Medicinal Chemistry 17:956-965 (1974).
McRory, J. E. et al., Molecular and functional characterization of a family of rat brain T-type channels, J. Biol. Chem. 275:3999-4011 (2001).
Mehrke, G. et al., The Ca++ channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels, Journal of Pharmacology and Experimental Therapeutics 271:1483-1488 (1994).
Neelands, T. R. et al., Functional expression of L-, N-, P/Q-, and R-type calcium channels in the human NT2-N cell line, J. Neurophysiol. 84(6):2933-2944 (2000).
Nilius, B. et al., A novel type of cardiac calcium channel in ventricular cells, Nature 316:443-446 (1985).
Nowycky, M. C. et al., Three types of neuronal calcium channel with different calcium agonist sensitivity, Nature 316:440-443 (1985).
Palmer, R. et al., Synthesis and x-ray crystal structure of 1,4-dihydro-2,6-dimethyl-4-(2′-isopropylphenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester: a nifedipine analogue, Bioorganic & Medicinal Chemistry Letters 6-18:2173-2176 (1996).
Peterson, B. Z. and Catterall, W. A., Calcium binding in the pore of the L-type calcium channels modulates high affinity dihydropyridine binding, J. Biol. Chem. 270:18201-18204 (1995).
Peterson, B.Z. et al., Calmodulin is the Ca2+dependent inactivation of L-type calcium channels, Neuron 22:549-558 (1999).
Pragnell. M. et al., Calcium channel beta-subunit bindings to a conserved motif in the I-II cytoplasmic linker of the alpha 1-subunit, Nature (London) 368:67-70 (1994).
Richard, S. et al., Inhibition of T-type calcium currents by dihydropyridines in mouse embryonic dorsal root ganglion neurons, Neuroscience Letters 132:229-234 (1991).
Rovnyak, G.C. et al., Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators, Journal of Medicinal Chemistry 38:199-129 (1995).
Soong, T. W. et al., Structure and functional expression of a member of low voltage-activated calcium channel family, Science (Washington DC) 260:1133-1136 (1993).
Stea, A. et al., Voltage gated calcium channels, in Handbook of Receptors and Channels; Ligand- and Voltage-Gated Ion Channels (North RA ed.) CRC Press, Inc., Boca Raton, Florida 113-152 (1995).
Takahashi, K. et al., Kinetic properties of T-type- Ca2+currents in isolated rat hippocampal CA1 pyramidal neurons, J. Neurophysiol. 65:148-155 (1991).
Tottene, A. et al., Functional diversity of P-type and R-type calcium channel in a rat cerebellar neurons, J. Neurosci. 16:6353-6363 (1996).
Tsien et al., Multiple types of neuronal calcium channels and their selective modulation, TINS 11:431-438 (1988).
Tsien, R. W. et al., Molecular diversity of voltage dependent Ca2+channels. Trends. Pharmacol. Sci. 12:349-354 (1991).
Wheeler, D.B. et al., Roles of N-type and Q type Ca2+channels in supporting hippocampal synaptic transmission, Science (Washington DC) 264:107-111 (1994).
Williams, M. E. et al., Structure and functional expression of alpha1, alpha2, and beta subunits of novel human neuronal calcium channel subtype, Neuron 8:71-84 (1992).
Zamponi, G. W., Antagonist binding sites of voltage-dependent calcium channels, Drug Development Research 42:131-143 (1997).
Alapati Srinivasa Rao
Bibbs Jeffrey A.
Pullela Phani Kumar
Rangappa Paramashivappa
Subbarao Pillarisetti V.
Davis Zinna Northington
Vittal Mallya Scientific Research Foundation
LandOfFree
1,4-dihydropyridine and pyridine compounds as calcium... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,4-dihydropyridine and pyridine compounds as calcium..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4-dihydropyridine and pyridine compounds as calcium... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3470180